Bristol Myers Squibb to Acquire 2seventy bio in $5.00/share All-Cash Deal

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Healthcare Services

Bristol Myers Squibb will acquire Turning Point Therapeutics in a $4.1 billion, all-cash transaction at $76.00 per share under a definitive merger agreement. The deal was originally expected to close in Q3 2022, and the acquisition was completed in August 2022.

Bristol Myers Squibb to Acquire Karuna Therapeutics in $14.0B Deal

December 22, 2023

Pharmaceuticals

Bristol Myers Squibb (BMS) and Karuna Therapeutics entered into a definitive merger agreement under which BMS will acquire Karuna for $330 per share in cash, valuing Karuna’s equity at about $14.0 billion (about $12.7 billion net of estimated cash acquired). The deal is expected to close in the first half of 2024, subject to customary approvals and regulatory conditions.

Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Deal

October 11, 2025

Biotechnology

Bristol Myers Squibb (BMS) has entered into an agreement to acquire Orbital Therapeutics, a privately held biotechnology company developing RNA medicines. The $1.5 billion cash deal will give BMS Orbital’s lead candidate OTX-201 and its proprietary RNA platform, supporting BMS’s efforts to advance in vivo CAR T and immunotherapy approaches.

Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).